文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

移植后环磷酰胺为基础的移植物抗宿主病预防减弱了相合与不相合无关供者移植结局的差异

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
PubMed 文献 · J Clin Oncol · 2024-07-17

该研究基于国际血液与骨髓移植研究中心2017至2021年数据,比较成人白血病或骨髓增生异常综合征患者接受相合无关供者(MUD)或单HLA位点不相合无关供者(MMUD)移植时,以移植后环磷酰胺(PTCy)为基础与以钙调神经磷酸酶抑制剂(CNI)为基础预防移植物抗宿主病(GVHD)的结局。结果显示PTCy方案下MUD与MMUD移植的总生存(OS)和无GVHD无复发生存(GRFS)相似,且PTCy较CNI方案改善MUD和MMUD移植的GRFS,扩大移植可及性。

要点

  • PTCy方案下MMUD与MUD移植的OS(HR 0.96,95%CI 0.823-1.11,P=.60)和GRFS(HR 0.90,95%CI 0.79-1.02,P=.1)相似。
  • MUD移植中PTCy较CNI方案改善OS(HR 0.88,95%CI 0.80-0.96,P=.004)和GRFS(HR 0.61,95%CI 0.57-0.66,P<.0001)。
  • MMUD移植中PTCy较CNI方案改善GRFS(HR 0.68,95%CI 0.60-0.76,P<.0001)。

核心结论

  • 使用PTCy时,MUD或MMUD移植可获得相当的总生存和无GVHD无复发生存,扩大所有种族和民族血统患者的移植可及性。

研究设计与样本

  • 研究为基于国际血液与骨髓移植研究中心2017至2021年报告的成人初次MUD或单HLA位点MMUD移植受者数据,比较PTCy与CNI为基础预防的3年OS和GRFS。
  • 共纳入10,025例移植受者:MUD联合CNI 7,272例,MUD联合PTCy 1,681例,MMUD联合CNI 613例,MMUD联合PTCy 459例。
  • 移植适应症为急性白血病(70.9%)或骨髓增生异常综合征(29.2%),患者中位年龄60.7岁(范围18.0-82.7),中位随访36.6个月(范围3.0-77.8)。

主要发现

  • 与MUD联合PTCy相比,MMUD联合PTCy的OS相似(HR 0.96,95%CI 0.823-1.11,P=.60),GRFS相似(HR 0.90,95%CI 0.79-1.02,P=.1)。
  • 与MUD联合CNI相比,MUD联合PTCy的OS改善(HR 0.88,95%CI 0.80-0.96,P=.004)。
  • 与CNI方案相比,PTCy方案在MUD移植中改善GRFS(HR 0.61,95%CI 0.57-0.66,P<.0001),在MMUD移植中改善GRFS(HR 0.68,95%CI 0.60-0.76,P<.0001)。
  • PTCy的获益不依赖于患者血统;全球注册分析显示纳入MMUD可增加供者可用性,无论受者血统。

临床怎么用

  • 原文结论指出使用PTCy时MUD或MMUD移植可获得相当的OS和GRFS,扩大所有种族和民族血统患者的移植可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)-based prophylaxis.METHODSThree-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021.RESULTSIncluded were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry.CONCLUSIONUse of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shaffer BC, Gooptu M, DeFor TE, et al. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024. PMID: 39018507. doi:10.1200/JCO.24.00184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。